|

To view ViaDerm Animation, click on the image above.
This video may take a few minutes to load.
TransPharma Medical’s implementation of its innovative RF-MicroChannel
Technology is the ViaDerm drug delivery system. Intended for home use, the
system consists of a reusable battery-operated handheld electronic control unit,
a disposable low-cost microelectrode array and a patch containing a drug.
The reusable device, with disposable microelectrode array attached, creates
the RF MicroChannels preparing the skin site for application of a proprietary
patch containing a drug. The drug then passively diffuses through the
RF-MicroChannels into the inner skin layer and from there to the systemic
circulation. The ViaDerm system is designed for an easy, seamless, one-handed
application.
The ViaDerm device is available in three sizes, depending on the desired dose
of drug to be delivered. All require only minimal initial patient training.
A ViaDerm System Walk-Through
 |
1. The 1 cm2 microelectrode array is snapped onto
the control unit. |
 |
2. The proprietary one-handed patch is then coupled
with the control unit. |
 |
3. The ViaDerm assembly is then gently
placed on the skin. Applying light pressure on the treatment site
creates the RF-MicroChannels within one second. Upon completion, a green
LED and beeping tone indicate that the RF-MicroChannels have been
successfully created. |
 |
4. After removing the ViaDerm from the treatment
site, the patch is folded gently over the frame. At this time, the
microelectrode array is disposed of using a quick release button which
ejects the used array. The drug patch is now securely affixed to the
treatment site, and the medication can now easily travel into the viable
skin layers via the RF-MicroChannels that have been formed. |
The completely functional ViaDerm drug delivery system is available for use
in clinical trials.
An Excellent Safety Profile
Six human studies conducted on a total of 136 healthy, adult volunteers were
conducted to assess the safety of the ViaDerm system.
Men and women of several age groups participated in the studies. The ViaDerm
system was applied to either the abdomen, upper arm or thighs of the
participants. The safety of the ViaDerm system was evaluated by measuring
irritation (erythema and edema) at the application site using the Draize
irritation index, and skin tolerability by measuring pain on a 100mm Visual
Analogue Scale (VAS) following ViaDerm treatment. In addition, the study
evaluated MicroChannel (MC) depth, assessed by a skin confocal microscope,
amongst various skin types and age groups.
The results demonstrated an excellent safety and tolerability profile with
only slight erythema and edema and negligible pain. In addition, average MC
depth was found to be nearly identical to that of the electrode length with a
low standard deviation. High uniformity in MC depth was also found across
various skin types, in all three age groups and both genders.
|